Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients

International Heart Journal

Volumn 55, Issue 6, 2014, Pages 499-505

  Liu, Bing ^a   Wang, Jiancheng ^a   Wang, Guoxing ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Angiotensin II; Arrhythmia; Atrial dilation; Atrial fibrosis; Atrial structural remodeling; Cardioversion; Clinical trial; Left atrial diameter; Type I carboxy terminal peptide

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMIODARONE; ANGIOTENSIN II; CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I CARBOXY TERMINAL PEPTIDE;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; SURVIVAL; ATRIAL FIBRILLATION; BLOOD; DIABETES COMPLICATIONS; DRUG EFFECTS; HEART ATRIUM; MIDDLE AGED;

AGED; ANGIOTENSIN II; ATRIAL FIBRILLATION; DIABETES COMPLICATIONS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART ATRIA; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; THIAZOLIDINEDIONES;

EID: 84924763759     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-107     Document Type: Article

References (57)

1. Lip GY, Varughese GI. Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol 2005; 105: 319-21.
2. Kato T, Yamashita T, Sekiguchi A, et al. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol 2006; 17: 890-4.
3. Swartz MF, Fink GW, Sarwar MF, et al. Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. J Am Coll Cardiol 2012; 60: 1799-806.
4. Goette A. Upstream therapy for atrial fibrillation in heart failure. Heart Fail Clin 2013; 9: 417-25. (Review)
5. Tziakas DN, Chalikais GK, Stakos DA, et al. Effect of angiotensin- converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension. Expert Opin Pharmacother 2007; 8: 2225-34.
6. Loffredo L, Angelico F, Perri L, Violi F. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovasc Disord 2012; 12: 107. (Review)
7. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 2011; 13: 610-25. (Review)
8. Shimano M, Tsuji Y, Inden Y, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008; 5: 451-9.
9. Kume O, Takahashi N, Wakisaka O, et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011; 8: 278-85.
10. Vaiopoulos AG, Marinou K, Christodoulides C, Koutsilieris M. The role of adiponectin in human vascular physiology. Int J Cardiol 2012; 155: 188-93. (Review)
11. Li G, Liu T. The therapeutic strategies of enhancing adiponectin and lowering leptin may be benefit to controlling atrial fibrillation. Med Hypotheses 2009; 73: 122.
12. Xu D, Murakoshi N, Igarashi M, et al. PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. J Cardiovasc Electrophysiol 2012; 23: 209-17.
13. Gu J, Liu X, Wang X, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011; 13: 1256-61.
14. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
15. Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888-95.
16. Kobayashi H, Shimamoto K, Moriguchi O. Radioimmunoassay of human plasma angiotensin II (author’s transl). Horumon To Rinsho 1979; 27: 665-9. (Japanese)
17. Munch G, Keis R, Wessels A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997; 35: 669-77.
18. Jahangir A, Lee V, Friedman PA, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30- year follow-up study. Circulation 2007; 115: 3050-6.
19. Spach MS, Boineau JP. Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: a major mechanism of structural heart disease arrhythmias. Pacing Clin Electrophysiol 1997; 20: 397-413. (Review)
20. Spach MS, Josephson ME. Initiating reentry: the role of nonuniform anisotropy in small circuits. J Cardiovasc Electrophysiol 1994; 5: 182-209. (Review)
21. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-4.
22. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54: 361-79.
23. Anyukhovsky EP, Sosunov EA, Plotnikov A, et al. Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis. Cardiovasc Res 2002; 54: 462-9.
24. Hayashi H, Wang C, Miyauchi Y, et al. Aging-related increase to inducible atrial fibrillation in the rat model. J Cardiovasc Electrophysiol 2002; 13: 801-8.
25. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originatingin the pulmonary veins. N Engl J Med 1998; 339: 659-66.
26. Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000; 101: 194-9.
27. Skanes AC, Mandapati R, Berenfeld O, Davidenko JM, Jalife J. Spatiotemporal periodicity during atrial fibrillation in the isolated sheep heart. Circulation 1998; 98: 1236-48.
28. Kallergis EM, Manios EG, Kanoupakis EM, et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol 2008; 52: 211-5.
29. Tziakas DN, Chalikias GK, Papanas N, et al. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. Europace 2007; 9: 589-96.
30. Sezai A, Hata M, Niino T, et al. Study of the factors related to atrial fibrillation after coronary artery bypass grafting: a search for a marker to predict the occurrence of atrial fibrillation before surgical intervention. J Thorac Cardiovasc Surg 2009; 137: 895-900.
31. Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90: 400-5.
32. Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S. Atrial extracellular matrix remodeling in patients with atrial fibrillation. J Cell Mol Med 2008; 12: 189-208.
33. Bishop JE. Regulation of cardiovascular collagen deposition by mechanical forces. Mol Med Today 1998; 4: 69-75. (Review)
34. Lopez B, Gonzalez A, Querejeta R, Diez J. The use of collage-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005; 23: 1445-51. (Review)
35. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
36. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
37. Van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117: 43-51.
38. Mukherjee R, Herron AR, Lowry AS, et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 2006; 97: 532-7.
39. Kato T, Yamashita T, Sekiguchi A, et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008; 19: 415-20.
40. Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L, et al. Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol 2012; 157: 397-402.
41. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation 2011; 124: 2264-74. (Review)
42. Gu J, Liu X, Wang QX, et al. Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts. Exp Cell Res 2012; 318: 2105-15.
43. Xiao HD, Fuchs S, Campbell DJ, et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004; 165: 1019-32.
44. He X, Gao X, Peng L, et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadiamediated downregulation of Smad 7. Circ Res 2011; 108: 164-75.
45. Khatib R, Joseph P, Briel M, Yusuf S, Healey J. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol 2012; 165: 17-24. (Review)
46. Xu D, Murakoshi N, Igarashi M, et al. PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving anti-oxidant capacity and reducing apoptosis in a rat model. J Cardiovasc Electrophysiol 2012; 23: 209-17.
47. Shimano M, Tsuji Y, Inden Y, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008; 5: 451-9.
48. Toblli JE, Cao G, Giani JF, Angerosa M, Dominici FP, Gonzalez- Cadavid NF. Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press Res 2011; 34: 20-33.
49. Gumieniczek A, Hopkała H, Roliński J, Bojarska-Junak A. Interleukin- 6 and oxidative stress in plasma of alloxan-induced diabetic rabbits after pioglitazone treatment. Immunopharmacol Immunotoxicol 2006; 28: 81-91.
50. Kamiński KA, Szepietowska B, Bonda T, et al. CCN2 protein is an announcing marker for cardiac remodeling following STZ-induced moderate hyperglycemia in mice. Pharmacol Rep 2009; 61: 496-503.
51. Puddu A, Sanguineti R, Durante A, Viviani GL. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T 15. Regul Pept 2012; 177: 79-84.
52. Oz Gul, Tuncel E, Yilmaz Y, et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabolism 2010; 59: 64-9.
53. Li F, Cai Z, Chen F, et al. Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products. Basic Res Cardiol 2012; 107: 306.
54. Saiki A, Ohir Ma, Endo K, et al. Pioglitazone decrease plasma angiotensin II concentration in type 2 diabetes. J Atheroscler Thromb 2010; 17: 651-7.
55. Subramanian V, Golledge J, Ijaz T, Bruemmer D, Daugherty A. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell specific interaction with PPAR{gamma}. Circ Res 2010; 107: 953-8.
56. Gu J, Liu X, Wang QX, et al. Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models. J Mol Cell Cardiol 2013; 65: 1-8.
57. Chao TF, Leu HB, Huang CC, et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol 2012; 156: 199-202.